N 6 -methyladenosine (m 6 A) has become a critical internal RNA modification, and it plays important roles in the development and progression of cancer [1] . m 6 A has also been found in diverse non-coding RNAs, such as microRNAs and long noncoding RNAs (lncRNAs) [2] . LncRNAs comprise a large class of RNA transcripts and are critical regulators of gene expression. The regulatory effectiveness of lncRNAs is closely associated with spatial expression, whose dysregulation often influences cancer

more »

... evelopment and progression [3] . For these reasons, global characterization of lncRNA spatial expression across tissues or cancers could improve our understanding of lncRNA functions. Recently, LncRNA Spatial Atlas (LncSpA) and landscape of m 6 A have been proposed as valuable resources to understand lncRNA and m 6 A regulatory functions across different tissues [4, 5] . However, we still lack understanding of the distribution and functions of m 6 A modification in lncRNAs, particularly the tissue-elevated (TE) lncRNAs. In this study, we aimed to systematically characterize the distribution and clinical relevance of m 6 A-related TE lncRNAs across tissues and cancer types. We found that TE lncRNAs were found to be regulated by m 6 A modification across tissues, particular brain tissues. We also investigated the correlation between expression of m 6 A regulators and TE lncRNAs, and found that numbers of m 6 A-related TE lncRNAs were associated with expression of m 6 A regulators. We assessed the clinical prognostic values of m 6 A-regulated TE lncRNAs. We identified several m 6 A-related TE lncRNAs as potentially useful markers for prognostic stratification. Our analysis highlights the importance of m 6 A modification in the regulation of lncRNA expression and helps bridge the knowledge gap between lncRNA expression and phenotypes.